iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD) was the recipient of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 215,000 shares, a drop of 14.5% from the December 15th total of 251,500 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 268,000 shares, the short-interest ratio is presently 0.8 days.

iCAD Stock Up 3.4 %

iCAD stock traded up $0.07 during mid-day trading on Friday, hitting $1.97. 698,862 shares of the company were exchanged, compared to its average volume of 201,917. The company has a market capitalization of $52.15 million, a PE ratio of -15.12 and a beta of 1.40. The business has a fifty day moving average of $1.84 and a 200 day moving average of $1.64. iCAD has a 1-year low of $1.18 and a 1-year high of $2.65.

Analyst Ratings Changes

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st.

Institutional Investors Weigh In On iCAD

A hedge fund recently bought a new stake in iCAD stock. Essex LLC acquired a new position in shares of iCAD, Inc. (NASDAQ:ICAD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned about 0.52% of iCAD at the end of the most recent quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.